Skip Navigation LinksHome > September 2013 - Volume 28 - Issue 5 > Open-label pilot study on vitamin D3 supplementation for ant...
International Clinical Psychopharmacology:
doi: 10.1097/YIC.0b013e3283628f98
Original Articles

Open-label pilot study on vitamin D3 supplementation for antipsychotic-associated metabolic anomalies

Thakurathi, Neelama; Stock, Shannonf; Oppenheim, Claire E.a; Borba, Christina P.C.a,b; Vincenzi, Brendaa; Seidman, Larry J.b,c,d,e; Stone, William S.b,c; Henderson, David C.a,b

Collapse Box

Abstract

Previous studies have linked vitamin D deficiency to hypertension, dyslipidemia, diabetes mellitus, and cardiovascular disease. The aim of this study was to investigate the short-term effects of vitamin D3 supplementation on weight and glucose and lipid metabolism in antipsychotic-treated patients. A total of 19 schizophrenic or schizoaffective patients (BMI>27 kg/m2) taking atypical antipsychotics were recruited and dispensed a 2000 IU daily dose of vitamin D3. On comparing baseline with week 8 (study end) results, we found a statistically significant increase in vitamin D3 and total vitamin D levels but no statistically significant changes in weight, glucose, or lipids measurements. Patients whose vitamin D3 level at week 8 was 30 ng/ml or more achieved a significantly greater decrease in total cholesterol levels compared with those whose week 8 vitamin D3 measurement was less than 30 ng/ml. These results suggest that a randomized trial with a longer follow-up period would be helpful in further evaluating the effects of vitamin D3 on weight, lipid metabolism, and on components of metabolic syndrome in antipsychotic-treated patients.

© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.